Clinical trials: Glaucoma,Open-Angle
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00293761
- Testing
- Travoprost, Investigational, Travoprost (TRAVATAN)
- Volunteers
- 109 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
- Trial name
- NCT00334750
- Testing
- There is no intervention in this study.
- Where
- 21 sites in Canada
- Volunteers
- 410 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Bimatoprost 0.01% in the Clinical Setting
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
- Trial name
- APPEAL-Taiwan (NCT01814761)
- Testing
- Bimatoprost 0.01%
- Where
- Taiwan
- Volunteers
- 312 people
- Sponsor
- Allergan
Open-angle Glaucoma, Ocular Hypertension
Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN
The purpose of this study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00798759
- Testing
- Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®), Latanoprost ophthalmic solution 0.005% (XALATAN®)
- Volunteers
- 236 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma
A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2
The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma.
- Trial name
- NCT00326079
- Testing
- Stent
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 61 people
- Sponsor
- Glaukos Corporation
Glaucoma
Circadian Ocular Perfusion Pressure and Ocular Blood Flow
The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients…
- Trial name
- NCT00800540
- Testing
- Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery
The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery.
- Trial name
- NCT07036510
- Testing
- TimoD implant, Injector system, Timolol eye drops 0.5%
- Where
- Panama
- Volunteers
- 42 people
- Sponsor
- EyeD Pharma
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-002.
- Trial name
- NCT02143843
- Testing
- Bimatoprost
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma
An Open Label Study Assessing the 24-hour Intraocular Pressure Pattern in PAC and PACG Patients, Before and After Laser Peripheral Iridotomy
The purpose of the study is to determine the relationship of the intraocular pressure patterns recorded during 2 sessions using Triggerfish, before and after elective laser peripheral iridotomy in angle closure glaucoma patients.
- Trial name
- NCT01906138
- Testing
- SENSIMED Triggerfish®
- Where
- India
- Volunteers
- 27 people
- Sponsor
- Sensimed AG
Open-angle Glaucoma
Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany
The aim of this prospective randomized study is to investigate the efficacy and safety of trabeculectomy with ologen Collagen Matrix versus trabeculectomy using mitomycin C (MMC) in patients with medically uncontrolled open angle…
- Trial name
- NCT01174420
- Testing
- Use of ologen Collagen Matrix in trabeculectomy, Use of Mitomycin-C in trabeculectomy
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Aeon Astron Europe B.V.
Open-angle Glaucoma, OAG
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. The purpose of this study is to assess adverse events (AEs) and changes in disease activity in participants with open-angle glaucoma…
- Trial name
- NCT05821855
- Testing
- XEN45 Glaucoma Treatment System, Trabeculectomy
- Where
- 13 sites in China
- Volunteers
- 120 people
- Sponsor
- AbbVie
Primary Open Angle Glaucoma, Ocular Hypertension
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or latanoprost in subjects with primary open…
- Trial name
- NCT01520116
- Testing
- Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Altheos, Inc.
Glaucoma, Open-Angle
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy.
- Trial name
- NCT00693485
- Testing
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant
- Where
- 2 sites in United States, Israel
- Volunteers
- 70 people
- Sponsor
- Allergan
Ocular Surface Disease, Primary Open Angle Glaucoma
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline to after 6 months of treatment…
- Trial name
- NCT04828057
- Testing
- Tafluprost, timolol maleate
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
Open Angle Glaucoma
TF for the Prediction of Visual Field Progression
Baseline 24-hour SENSIMED Triggerfish (TF) recordings as well as functional and structural vision tests measured prospectively every 3 months over a 2-year period, will be used to model TF's ability to serve as a risk factor for…
- Trial name
- NCT03047239
- Testing
- SENSIMED Triggerfish
- Sponsor
- Sensimed AG
Open-angle Glaucoma, Ocular Hypertension
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an…
- Trial name
- NCT00759239
- Testing
- Travoprost 0.004% / Timolol maleate 0.5%
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle
A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma
To prospectively compare the clinical effect of the OMNI surgical system in eyes with Open Angle Glaucoma.
- Trial name
- NCT04616573
- Testing
- OMNI® Surgical System, iStent inject
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Sight Sciences, Inc.
Primary Open Angle Glaucoma, Open Angle Glaucoma
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
The goal of this clinical trial is to show non-inferiority of the MIMS® device/procedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open…
- Trial name
- NCT06313749
- Testing
- Minimally Invasive Micro Sclerostomy Device
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Sanoculis Ltd
Glaucoma, Open Angle, Ocular Hypertension
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate.
- Trial name
- NCT00804648
- Testing
- Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vistakon Pharmaceuticals